Evogene (EVGN) Accumulated Expenses (2016 - 2026)

Evogene has disclosed Accumulated Expenses across 11 years of filings, most recently posting $911000.0 for Q2 2026.

• In Q2 2026, Accumulated Expenses fell 48.62% year-over-year to $911000.0; the TTM figure through Jun 2026 stood at $911000.0 (down 48.62% YoY), while the FY2025 annual figure was $861000.0, down 53.93% from the prior year.
• Accumulated Expenses came in at $911000.0 for Q2 2026 at Evogene, down from $922000.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $2.7 million in Q1 2022 to a low of $861000.0 in Q4 2025.
• Average Accumulated Expenses over 5 years is $1.9 million, with a median of $2.1 million recorded in 2023.
• Year-over-year, Accumulated Expenses climbed 27.68% in 2023 and plunged 53.93% in 2025.
• Over 5 years, Accumulated Expenses stood at $2.0 million in 2022, then gained by 27.68% to $2.5 million in 2023, then decreased by 26.33% to $1.9 million in 2024, then sank by 53.93% to $861000.0 in 2025, then increased by 5.81% to $911000.0 in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $911000.0 in Q2 2026, $922000.0 in Q1 2026, and $861000.0 in Q4 2025.